Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractBackground: Cariprazine is a new atypical antipsychotic drug approved for the treatment of schizophrenia and bipolar disorders. Methods: we searched the published randomized controlled-trials (RCT) to review cariprazine efficacy and tolerability using the databases (PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials) for cariprazine role in managing the following psychiatric conditions (schizophrenia, bipolar mania, bipolar depression and major depressive disorder). A meta-analysis was conducted using the identified 13 clinical trials to assess efficacy using with the outcomes: positive and negative syndrome scale (PANSS), clinical global impressions – severity of Illness (CGI-S), young mania rating scales (YMRS), Montgomery Asberg depression rating scale (MADRS) and Hamilton rating scale for depression (HAM-D). The risk of discontinuation due to adverse effects and common side effects were examined. Results: The mean difference in change from baseline for PANSS was -6.23 [95% Confidence Interval (CI) -7.18, -5.28] favoring cariprazine treatment (p<0.00001). Similarly, mean difference for CGI-S was -0.36 [95% CI -0.41, -0.30], YMRS -5.64 [95% CI -6.86, -4.43], MADRS -1.43 [95% CI -1.88, -0.99] and HAM-D -1.52 [95% CI -2.28, -0.76]. The risk ratio (RR) of discontinuing due to adverse events was 1.18 [95% CI 1.01, 1.38] meaning risk increased by 18% in cariprazine group with RR for EPS related side effects 2.82 [95% CI 2.47, 3.22] reflecting an increased risk of experiencing EPS related side effects by 182%. Cariprazine was also associated with an increased incidence of side effects such as akathisia, nausea and insomnia. Conclusion: Cariprazine demonstrates significant improvements in symptom intensity control in patients suffering from psychiatric conditions including schizophrenia, bipolar disorders and depression and is considered well-tolerated with similar rates of trials discontinuation; however, cariprazine was associated with a higher risk of EPS side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting psychiatric patients care.
CitationAntoun Reyad, A., Cooper, H. and Mishriky, R. (2020) Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials, Psychiatria Danubina, 32(1), pp. 36-45 https://doi.org/10.24869/psyd.2020.36
PublisherMedicinska naklada Zagreb
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/